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 The expression of C-X-C Chemokine Receptor 4 (CXCR4) has been correlated 
with increased metastatic potential of cancer cells. CXCR4 increases tumor malignancy 
by encouraging tumors cells to migrate to distal organs expressing its cognate ligand, 
CXCL12, facilitating metastasis. Thus, targeting the CXCR4/CXCL12 signaling axis 
provides a good strategy to inhibit the metastatic spread of tumor cells and slow cancer 
progression. Various studies suggest that cannabis may have anti-proliferative as well as 
anti-metastatic properties, though a biochemical mechanism describing how this occurs 
has yet to be discovered. Our lab has confirmed that agonist-bound CXCR4 and agonist-
bound Cannabinoid Receptor 2 (CB2) can form heterodimers that play a role in 
decreasing cancer cell migration. Simultaneous treatment of the breast cancer cell line, 
MDA-MB-231 and the prostate cancer cell line PC-3, with CXCL12 and AM1241, a 
synthetic ligand for CB2, desensitizes the intrinsic cellular response to migrate toward 
areas of high CXCL12 concentration. Furthermore, through co-immunoprecipitation and   
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proximity ligation assays (PLA), we have determined that there is increased interaction 
between the two receptors with co-stimulation of respective agonists, providing evidence 
for the therapeutic notion that treating tumors that endogenously secrete CXCL12 with 
exogenous ligands for the cannabinoid can induce dimerization. Moreover, when CXCR4 
and CB2 were activated simultaneously with various agonists, decreases in migration 
were observed, confirming that the regulatory activity was receptor-based, not agonist-
based. Finally, to determine whether simultaneously–treated, dimerized receptors 
inhibited activity of respective receptors, calcium mobilization assays to determine G-
protein coupled receptor activation were employed. Results showed that transiently 
activated calcium levels were significantly lower in response to simultaneous treated cells 
when compared to cells treated with their individual ligands. Phosphorylation of ERK 
and AKT were abrogated in response to simultaneous stimulation indicating loss in 
downstream signaling. Therefore, we believe that the interaction of CB2 with CXCR4 
may play a role in inhibiting the cells response to CXCL12, leading to a loss in metastatic 
potential of cells expressing these receptors.  
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 A tumors ability to move from a primary site to a secondary site is defined as 
metastasis (4). There are many factors that are involved in the initiation of this process; 
however, once the tumor gains the ability to metastasize, the degree of malignancy of the 
tumor is increased significantly and is then referred to as a metastatic cancer (5).  The 
inhibition of metastasis is one of the major therapeutic challenges in the field of cancer 
research.  Though inhibition of cancer metastasis is not singularly curative, inhibition of 
metastasis does provide a patient with a more positive prognosis by halting the spread of 
the disease until it can be excised or pharmacologically treated. The expression of various 
genes is highly associated with cancer metastasis and advanced progression, one of them 
being the CXCR4 (C-X-C chemokine receptor) gene (6). CXCR4 encodes a chemokine 
receptor protein that induces cells to migrate towards areas containing high 
concentrations of its cognate ligand, the stromal-derived factor 1(CXCL12 or SDF-1) (7).  
CXCR4 is most commonly associated with the immune system and has an innate role in 
the recruitment of leukocytes toward sites of hematopoiesis during embryogenesis (7). Its 
ligand is highly expressed in the brain, thymus, heart, lung, liver, kidney, spleen, and 
bone marrow (8).   
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Cancer is usually initiated by gene mutations that lead to uncontrolled and 
unregulated cell division. With increases in cell division, there is increased DNA 
synthesis and replication (9). Due the extensive size of the human genome, increases in 
unregulated DNA replication will inevitably lead to numerous mutations, increasing the 
heterogeneity of the tumor and activating genes that were once silenced or silencing 
genes that were once active (9). It is through this process that scientists believe that 
CXCR4 expression is initiated in many cancers. Cancers expressing CXCR4 can now 
effectively utilize the CXCR4/SDF-1α pathway and provide cells with a mechanism to 
metastasize towards sites with high concentrations of SDF-1α, such as the brain or the 
bone marrow, making targeting and treating the cancer exponentially harder (10, 11).  
Finding ways to disrupt this pathway will, in theory, decrease the number of 
metastases toward the bone marrow and brain (11). Antagonists have been developed to 
inhibit the activation of CXCR4; however, their effect is usually global which targets 
cancers as well as cells that innately express CXCR4 for a non-cancer related functions 
(12). Being able to target CXCR4 in cancer without affecting CXCR4-expressing 
leukocytes is one of the challenges of cancer. 
Cannabinoids have garnered a lot of attention recently due to their therapeutic 
relevance in a number of diseases (13). Studies have shown that cannabinoids may have a 
role in preventing cancer proliferation as well as metastasis (14). Delineating how 
cannabinoids may exert this effect on cancer cells has yet to be fully understood and is 
important due the potential side effects cannabinoid treatments could elicit on other 
systems of the body. A potential mechanism that elucidates how cannabinoids regulate 
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cancer progression may be achieved by taking a closer look at the cannabinoid receptor. 
The cannabinoid receptors are members of the G-protein coupled receptor (GPCR) 
family and recent studies have reported that when GPCRs form heterodimers, the normal 
activity of the GPCRs can be altered, either increasing, decreasing or totally abrogating 
downstream signaling (2). We have observed that activation of the Cannabinoid Receptor 
2 (CB2) leads to an abrogation of CXCR4-mediated migration when stimulated 
simultaneous by CXCR4 (15). It is on this theory that the hypothetical basis of this 
dissertation is established; CXCR4 and the Cannabinoid Receptor 2 form heterodimers 
that impede SDF-1α -mediated downstream cellular response.  Our hypothesis was 
experimentally tested through the investigation of the following aims: 
Specific Aim 1: To investigate whether CXCR4 and CB2 form heterodimers when they 
are simultaneously activated. 
Specific Aim 2: To determine if CXCR4/CB2 heterodimers play a role in the abrogation 
of migration and downstream signaling observed when cells are treated simultaneously. 






LITERATURE REVIEW  
 
Cancer Metastasis  
Cancer is the uncontrolled growth of cells that would be, normally, otherwise, in a 
quiescent phase of their cell cycle. This unregulated growth usually leads to the formation 
of a tumor that can be characterized as benign or malignant. Benign tumors are non- life-
threating tumors that have failed to invade the basement membrane of the organ in which 
they originated. Malignant tumors are tumors that have invaded the basement membrane 
and produced the angiogenic factors that recruited blood vessels that have vascularized 
the tumor (16). Once the tumor becomes vascularized, cancer cells can now degrade the 
basement membrane and obtain access to the rest of the body, via the circulatory system. 
Most of the time, cancers are initiated by various mutations that initially lead to either the 
inhibition of apoptosis by inactivating tumor suppressing genes or the activation of 
various transcription factors that influence the cell to start going through the different 
phases of the cycle. The abnormal increase in cellular division tends to lead to an 
increased probability of genetic mutations which then amplifies tumor heterogeneity (17). 
Most cancers are caused by environmental factors, though a minority of cancers are 
hereditary in nature. The most common environmental factors that contribute to 
carcinogenesis are smoking, diet, obesity, infections, radiation, stress, lack of physical 
activity, and environmental pollutants (18). A study published in Nature determined that 
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the most commonly mutated genes found in cancer is the TP53 gene, a tumor suppressor 
that regulates whether cell goes through apoptosis after DNA damage (19). This mutation 
is so widespread in cancers because once the cell has lost the machinery to regulate 
whether a mutation will eventually be deleterious, the cell begins to activate cell survival 
genes and eventually passes the deleterious mutation down to each of its subsequent 
daughter cells. Without, mutation regulatory genes such as p53, to signal apoptosis, many 
more genes are free to become mutated and gain function, despite the fact that they aren’t 
supposed to be activated within that cell. One of the many genes that are actively 
repressed by the wild–type form of p53 but is overexpressed when p53 is mutated is the 
chemokine receptor, CXCR4 (20). CXCR4 plays an important role in the metastatic 
tumor and its expression is usually associated with a poor prognosis. 
The Innate Role of CXCR4 
 CXCR4, or C-X-C Chemokine Receptor 4, is rhodopsin-like 352 amino acid G-
protein coupled receptor (GPCR) that is part of the chemokine receptor family. The 
natural role of CXCR4 is to provide chemotactic activity for cells that express the gene. 
Expression of CXCR4 is usually relegated to immune cells, such as lymphocytes and 
hematopoietic stem cells, providing guidance towards bone marrow. CXCR4 also plays a 
role in neuronal guidance during embryogenesis by chemotactically directing nerve 
formation toward their requisite sites of innervation. When the nerve has been fully 
formed and maturation of the neuron occurs, the expression of CXCR4 is diminished as 
CXCR4’s role has been realized (21). Along with neuronal guidance, CXCR4 plays and 
important role in organogenesis and vascularization. A study done by Tachibana et al. 
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found CXCR4 to be essential in the vascularization of the gastrointestinal tract of 
mice(22). 
Activated CXCR4 initiates downstream signaling in the canonical (G-protein 
coupled receptor) GPCR way. Ligand binding causes conformational change of the 
receptor, which in turn allows the Gi subunit to exchange its bound GDP for a GTP. This 
then leads to a dissociation of the trimeric G-protein and eventually the activation of 
activation of CXCR4 leads to the inhibition of adenylyl cyclase and the decrease of 
cAMP levels. The Gß dissociates to activate phospholipase-C- (PLC-) and 
phosphoinositide-3 kinase (PI3K) ultimately leading to the regulation of various cellular 
processes(3). Common downstream signaling pathways associated with activated 
CXCR4 are the MAPK, JAK/STAT, PI3K pathways that eventually lead to cell 
migration, transcription and cell adhesion (see Figure 2-1).  
                   
 
Figure 2-1. CXCR4 Signaling Pathway. The canonical CXCR4 signaling is initiated 
by the binding of CXCL12 (SDF1α) to the receptor. Activated CXCR4 can signal 
through various pathways to regulate cell migration and transcription, including but 
not limited to the MAPK, JAK/STAT, and PI3K pathways (3). 
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CXCR4’s Role in Cancer Metastasis 
CXCR4 is usually expressed in hematopoietic cells and in neuronal cells during 
embryogenesis. However, scientists have found 23 different cancer tissues have been 
found to express the CXCR4 gene and it is actually the most commonly expressed 
chemokine receptor(23). The expression of CXCR4 in these cancers is particularly 
interesting because in the majority of cases the surrounding normal tissue little to no 
CXCR4 expression. There are a number of speculations as to why this may be the case; 
however the most widely accepted notion is that due to the fact that cancer cells are 
rapidly dividing and quickly depleting resources such as glucose and O2. This rapid 
depletion of resources soon leads to hypoxic conditions, triggering various signaling 
pathways within the cancer. One pathway, in particular, that is triggered by the hypoxic 
conditions is the hypoxia inducible factor 1(HIF-1) pathway. HIF-1 is a protein that 
recognizes when a cell reaches hypoxic conditions and begins to induce the expression of 
genes that will attempt to help the cell survive, one of these genes being CXCR4.  
CXCR4’s chemotactic abilities have hypothetically and experimentally linked it 
to cancer metastasis. Various studies have been done using cancer cell lines to determine 
the effects CXCR4 expression has on the progression of cancer and cancer metastasis. 
Activation of CXCR4 has been linked to the expression of matrix metalloproteases 
(MMPs) that aid in degrading the surrounding extracellular membrane making invasion 
and migration more likely (24). Studies have also been done that show that cancers which 
express CXCR4 migrate with significant frequency to areas that have high concentrations 
of its cognate ligand, SDF-1. Statistically, breast cancer are the most likely to follow 
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this pattern of metastasis; correlating with the fact that the majority of breast cancer 
metastases are found within the lymph nodes, liver, bone marrow, and lungs, all areas 
that express high levels of SDF-1 (25). Other cancers that have been found to 
metastasize to areas that have high SDF-1  concentrations are small cell lung cancer, 
thyroid, neuroblastoma, hematological and hepatic cancers (26-28). In a study done by 
Sun et al., increased expression of CXCR4 has been correlated with increasing prostate 
cancer aggressiveness (29). Because of this correlation with metastasis, CXCR4 has been 
and will continue to be a target for metastasis-related therapy. 
Cannabinoids and Cannabinoid Receptors  
Cannabinoids are chemical compounds that can activate cannabinoid receptors. 
Cannabinoids fall into three major classes, phytocannabinoids, endocannabinoids, and 
synthetic cannabinoids. Phytocannabinoids are chemical compounds derived from a plant 
based source that activate cannabinoid receptors, while endocannabinoids are chemical 
compounds produced naturally within the body, and synthetic cannabinoids are chemical 
compounds that are artificially manufactured. Each of these categories of cannabinoids 
have the unique ability to bind and activate the cannabinoid receptors. The most common 
and well-studied cannabinoids are tetrahydrocannabinol (THC), cannabinol (CBD) and 
cannabidiol (CBD). 
There are two well established cannabinoid receptors: cannabinoid receptor 1 
(CB1) and cannabinoid receptor 2 (CB2) though there is another cannabinoid receptor 
that has been found recently, the orphan receptor GPR55 (30). CB1 is the more 
understood the two receptors and is responsible for the psychoactive effects one tends to 
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correlate with marijuana use. The CB1 receptor is highly expressed within the nervous 
system, specifically the brain. CB1’s main function is to regulate the release of various 
neurotransmitters within the brain to suppress excessive neuronal activity. CB1 is a G-
protein coupled receptor that is associated with Gi subunit of the trimeric G-protein and 
once activated it suppresses the production of cAMP. The second cannabinoid receptor is 
expressed more in the immune system than in the nervous system and is therefore 
associated with immunoregulatory functions (31). The primary endocannabinoid for the 
CB2 receptor is 2-arachidonoylglycerol (2-AG) (32). Like the CB1 receptor, CB2 is 
associated with the Gi subunit of the associated trimeric G protein and has a role in 
inhibiting adenylyl cyclase decreasing the cAMP levels in the cell. 
The Role of Cannabinoid Receptor 2 in Immunity 
The majority of research pertaining to the CB2 receptor has analyzed its role on 
the immunological activity of leukocytes. It has specifically been involved in various 
immune functions including immune suppression, induction of apoptosis, and induction 
of cell migration. The greatest density of the CB2 receptor expression is found within the 
spleen, however there are also high concentrations CB2 mRNA in the tonsils as well as 
the thymus gland (33). CB2’s role in the immune system was primarily mediating 
cytokine release (34). Activated CB2 signals through the same mechanism as CXCR4 
being that they are both GI associated GPCRs, indicating that adenylyl cyclase is 
inhibited when the receptor is activated. The G subunits dissociate from the activated 
receptor and go on to activate the MAPK/ERK pathway (35). It is speculated that it is 
through this pathway that activated CB2 mediates the changes in the migration of 
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immune cells, however because there are so many different ligands for this receptor, the 
pathway that is activated depends on which ligand is present on the receptor. Specifically, 
CB2 activation is thought to be associated with immunosuppresive activity because it 
downregulates the production of cAMP, the main activator of the CREB (cAMP 
response-element binding protein) transcription factor. Once CREB is activated it plays a 
major role in the expression of immunoregulatory genes however, with the decrease in 
cAMP less CREB is activated leading to the modulation of genes that regulate immune 
suppresion in immune cells(36, 37). 
G-protein Coupled Receptor (GPCR) Heterodimerization 
GPCRs are 7-transmembrane domain proteins that are linked to a 3-member G-
protein complex, usually found on the cell membrane. These proteins are involved in a 
variety of functions ranging from taste recognition to chemo-attraction in immune cells. 
GPCRs have been canonically known to function as monomers and homodimers but an 
increasing amount of evidence is proving that heterodimerization of these proteins play 
an important role in biological function (2, 38). GPCRs respond to a diverse number of 
external stimuli and their ligands vary in size as well as structure (39). Due to their 
ubiquitous expression in all types of cells, they are the targets of approximately 40% of 
all modern medicinal drugs (40). Depending on which G-protein is activated, GPCRs 
may elicit beneficial or detrimental effects in a number of biological scenarios, including 
cancer progression. GPCRs are canonically known to function as monomers and 
homodimers, however an increasing amount of evidence has been accumulated showing 
how heterodimerization of GPCRs play an important role in biological function. This has 
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become an area of scientific interest recently because encouraging two functionally 
different receptors to partner together to elicit a change in their function, understanding 
and being able to exploit this phenomenon could be very beneficial to pharmacological 
advances in medicine.  
Heterodimerization of GPCRs can occur through ontogeny or through ligand-
promoted regulation. In an ontological system of heterodimerization, the two GPCRs are 
bound while being assembled within the Golgi apparatus and then sent to the cell 
membrane. In a ligand regulated system of GPCR heterodimerization the respective 
ligands need to be bound to the receptor in order for heterodimerization to occur (see 
Figure 2-2). 
            
 
 GPCR heterodimerization has been found to either increase normal function of 
one or both of the bound receptors (KOR-DOR receptors) (41), decrease function (MT1-
GPR50 receptors) (42) or change the function of the dimer altogether (T1R2-T1R3)(43). 
Research into GPCR heterodimerization is an emerging field of study and the 
Figure 2-2. Formation Pathways of G-Protein Coupled Receptor Heterodimers (2). 
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implications of this research will have far reaching effects in the advancement of 
medicine and pharmacology. Understanding how specific GPCR’s interact and how the 
interaction functionally regulates their activity is important and will have an invaluable 
impact in the scientific world. 
Published data by Milligan et.al has shown that the Opioid Receptor 1(OR1) and 
Cannabinoid Receptor 1 (CB1) heterodimerize and that the OR1 antagonist negatively 
affects the activity of the CB1 receptor (44). Data from Pello et. al has shown that 
simultaneous stimulation of the δ Opioid Receptor (DOR) and CXCR4 leads to receptor 
silencing through heterodimerization (45). Agonists of the cannabinoid receptors, like 
THC, have also been found to have a regulatory role on the transcriptional activity of 
CXCR4 (46). Research into GPCR heterodimerization is an emerging field of study and 
the implications of this research will have far reaching effects in the advancement of 
medicine and pharmacology. 
The Innate Roles and Pharmacological Relevance GPCR Heterodimers 
Though being able to understand and delineate the parameters in which GPCRs 
form heterodimers is a relatively new area of science, scientists have found that naturally 
occurring GPCR heterodimers is a common occurrence within the body. The ability to 
taste differences in food, for example, is mainly due the fact the GPCRs can form 
heterodimers. The receptors on taste buds that recognize the difference between sweet 
and umami substances are actually a combination of two different types of taste 
receptors; T1R2-T1R3 and T1R1-T1R3, respectively (47). It is only through the 
heterodimerization and the subsequent downstream signaling of these receptors that we 
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can perceive the difference in sweet and umami tastes.  Another example of how innate 
GPCR heterodimers play a role in natural human life is the  opioid receptor (MOR) and 
 opioid receptor (DOR) heterodimer. These receptors are two of the three opioid 
receptors that recognize and translate activation from opioid ingestion in a chemical 
signal. Scientist have found that when they co-express MOR and DOR in HEK293 cells 
it resulted in a 10-fold reduction in binding affinity of a synthetic MOR-selective agonist, 
DAMGO(48). This is relevant because it could explain the why in vivo and in vitro 
models produce mixed results during pharmacological applications of various drugs. A 
clinical application of this information could hypothetically explain why people who 
have a natural expression of both the receptors may be less likely to develop a 
dependency on these drugs. 
Table 2-1 shows how there are numerous examples of GPCR heterodimers in the 
body and the role they play in our everyday lives. Because GPCRs are the targets for 
nearly 40% of all drugs available in modern medicine, continuing to understand how 
these GPCRs are forming heterodimers and under what circumstances, may provide us 
with insight into new and better pharmaceutical therapies for a vast array of conditions 
and diseases. The ubiquitous nature of GPCRs allows them to form unique heterodimers 
with other GPCRs within their respective subfamilies. As seen in Table 2-1, GPCR 
heterodimers can be involved in processes as simple as increases in the amount of cAMP 
production induced by a ligand to processes as specific as the shifting the G-protein 





GPCR Internalization and Its Role in Heterodimerization 
Receptor-mediated endocytosis is the way most cells regulate GPCR cell surface 
expression. In this process, agonist-activated receptors are quickly and often reversibly 
displaced from the cell membrane and trafficked into the cell via endosome formation. 
Once activated, ligand-receptor complexes are internalized within the cell through 
specialized membrane regions called clathrin coated pits. Activated ligand-receptor 
complexes are clustered in these clathrin coated pits after GRK (G-protein receptor 
specific serine/threonine kinase)-mediated phosphorylation and β-arrestin binding (49). 
The cell membrane around the activated receptors forms invaginations, which are 
eventually pinched off and fused with early endosomes. 
Table 2-1. GPCR Heterodimers and Their Biological Effects (1) 
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β-arrestin’s major function is the trafficking of activated GPCRs to the clathrin 
coated pits where it binds to β2-adaptin and clathrin (50, 51). β-arrestin has also been 
found to play a role in dictating the intracellular trafficking fate of activated receptors. 
Once endocytosis occurs, receptors are dephosphorylated and either recycled to the cell 
membrane as functional receptors or trafficked to lysosomes for degradation (49). 
Whether the receptor is recycled or degraded is determined by Rab GTPase activity. The 
Rab family of Ras-like small G-proteins is the largest and most diverse of this group 
comprised of approximately 60 members (49, 52). 4 members of this family have been 
found to play a major role in regulating the trafficking of internalized GPCRs to early and 
late recycling endosomes as well as lysosomes. These proteins are Rab4, Rab5, Rab7 and 
Rab11 GTPases and they each play a role in varying stages of GPCR internalization and 
trafficking (49).  
To review, receptor internalization can either operate as a mechanism for receptor 
re-sensitization by recycling receptors to the cell membrane (mediated by Rab4 and 
Rab11 activity) or initiate receptor desensitization by serving as the first step towards 
trafficking the receptors to lysosomes for degradation (mediated by Rab7 activity)(53). 
Studies have shown that when GPCR’s interacted, internalization of the interacting 
GPCRs either decreased or were totally inhibited (54, 55). A study done by Lavorie et al. 
determined that when both the 1 and 2 adrenergic receptors were expressed in HEK-
293 cells, 1 inhibited the agonist-dependent internalization of 2 receptors (54). Also, in 
a study done by Jordan et al., they found that when 2 adrenergic receptors and both  
and  opioid receptors were expressed, they formed heterodimeric complexes. However, 
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2 receptors, when co-expressed with  receptors, undergo neither opioid- nor 









Chemicals and Reagents 
The following reagents were from Thermo Fisher Scientific: Pierce™ Co-
Immunoprecipitation Kit (26149) and Keratinocyte-SFM (17005-042). Human 
recombinant SDFlα (300-28A) was purchased from PeproTech. Human antibodies mouse 
monoclonal IgG1 anti-CXCR4 (sc-53534) and rabbit polyclonal anti-CXCR4 (sc-9046) 
were from Santa Cruz. Protein A/G PLUS-Agarose (sc-2003) was also purchased from 
Santa Cruz Biotechnology, Inc. The following reagents and human antibodies were from 
Sigma Aldrich: Triton X-100 (T8532); mouse monoclonal anti- αTubulin (T5168); 2-
mercaptoethanol (M3148-25ml); PMA (P1585-1MG); AMD3100 octahydrochloride 
hydrate (A5602-5MG); DUOlink® Proximity Ligation Assay (DUO92101-1KT). Rabbit 
anti-RAB5 (3547T), Rabbit anti-ß-arrestin (C16D9) were purchased from Cell Signaling 
Technology, Inc. Hemacolor rapid staining solution (111661) was purchased from EMD 
Millipore. Rabbit anti-CB2 receptor polyclonal antibodies (101550), and the CB2 agonists, 
AM1241 (10010118) and JWH-015 (10009018) were purchased from Cayman Chemical. 
The CB2 antagonist AM630 (10006974) was also purchased from Cayman Chemical. 
PCR kit with Taq Polymerase (N555-kit) was purchased from AMRESCO. RPMI 1640 
(10-040CV) and DMEM (10-013-CV) was from Corning. RIPA Lysis Buffer  
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(N653-100ML) as well as CHAPS (0465-10G) were purchased from AMRESCO. FM® 
4-64 Dye (N-(3-Triethylammoniumpropyl)-4-(6-(4-(Diethylamino) Phenyl) Hexatrienyl) 
Pyridinium Dibromide) (T13320) was purchased from Thermo Fisher Scientific. 
FluoForte calcium assay was purchased from Enzo Life Sciences. All secondary 
antibodies were from Jackson ImmunoResearch Laboratories, Inc.  
Western Blot Analysis  
(MDA-MB-231, PC-3, and HEK-293) Cells were plated in 6 well plates at a 
density of 3x105 cells per well. Cells were treated as indicated and lysed and cell lysate 
was collected. Lysates were quantified and loaded into 10% SDS-PAGE. Lysates were 
blotted on a nitrocellulose membrane and subjected to overnight incubation with 
indicated primary antibodies: mouse anti-CXCR4 (Santa Cruz Biotechnology), rabbit 
anti-CXCR4 (Santa Cruz Biotechnology), polyclonal rabbit anti-CB2 (Cayman 
Chemical), mouse anti-SDF-1α (Santa Cruz Biotechnology), monoclonal mouse anti-α-
Tubulin (Sigma-Aldrich). Following washings, the nitrocellulose membrane was 
incubated with indicated secondary antibodies: Peroxidase-conjugated AffiniPure 
donkey-anti rabbit (Jackson ImmunoResearch), Peroxidase-conjugated AffiniPure 
donkey anti-mouse (Jackson ImmunoResearch). α-Tubulin was used as a loading control.  
Human Prostate and Breast Cancer Cell Lines  
The prostate cancer cell lines PC3 (CRL-1435) and the breast cancer line MDA-
MB-231 (HTB-26) were all obtained from American Type Culture Collection (ATCC) 
and maintained per manufacturer’s instructions. In brief, prostate cancer and breast 
cancer cell lines were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640; 
supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids, 1% 
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antibiotic- antimycotic and 1% L-glutamine). All cells were maintained in a 37°C, 5% 
CO2. Serum starvation conditions consisted of culturing in reduced serum medium 
(unsupplemented DMEM or phenol-free RPMI containing 1% L-glutamine and 0.2% 
FBS) for 24 hours. 
Co-Immunoprecipitation Analysis 
1x106 cells (MDA-MB-231, PC-3) were plated in P-100 dishes and were serum-
starved for 24 hours. Cells were treated for 15 mins with Ctrl (RPMI 1640), SDF-1α 
(100ng/mL), AM1241 (1μM), or SDF-1α+AM1241 simultaneously. Cells were then 
lysed using 0.01% CHAPS (Amersco) lysis buffer (wt/vol) and RIPA (Amresco) Buffer 
(1:1 dilution) in a final volume of 500µL and cell lysate was collected. Cell lysates were 
then incubated with polyclonal mouse anti-CXCR4 antibody (1:100, Santa Cruz 
Biotechnology, Inc.) for 1 hr. for 4°C under gentle agitation and Protein A/G PLUS 
Agarose Beads (1:50, Santa Cruz Biotechnology, Inc.) were added and left overnight at 
4°C under gentle agitation. The immunoprecipitates were separated from supernatants by 
centrifugation at 1,000 g for 5 min (4°C) and washed three times with Tris-buffered 
saline. The resulting pellets were mixed with Laemelli buffer. Heated for 4 min at 100°C 
and centrifuged for remove protein A/G-agarose. Immunoprecipitates were then run on a 
10% SDS-PAGE, transferred to a nitrocellulose membranes and immunoblotted with 
rabbit anti-CB2 antibody, rabbit anti-EP2 antibody, or mouse anti-CXCR4 antibody.  
Transwell Migration Assays 
 After a 24-hour serum starvation, 4x104 cells were seeded in the upper chamber of 
transwell inserts, and either SDF1α (100ng/ml), AM1241 (1μM), CXCL1 (100ng/ml), 
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JWH-015 (1μM) or any combination of the preceding, diluted in RPMI, were added to 
lower chambers. Cells were allowed to migrate for 5 hours in 5% CO2 at 37°C. After 
incubation, non-migrated cells in the inner-upper chambers were cleaned with a cotton 
swab, and cells attached to the outer-upper chamber were stained with HEMA 3 System. 
Five representative fields of each insert were counted on a light microscope and the 
migration index was calculated and graphed as the x-fold change in migration observed 
over control cells. Experiments were performed at least thrice and the mean and standard 
error were calculated.  
Calcium Mobilization Assays 
 Cells were plated 6.0 x 104 cells per well in a 96 well plate (1x106 cells total). 
Cells were serum-starved for 24 hours with phenol free RPMI. Starvation media was 
removed and FluoForte™ Dye Loading Solution (Enzo Life Sciences, Inc.) was added to 
each well (100µl/well for 96-well plates). 96-well plate was then wrapped in foil and 
incubated 45 min at 37°C temperature and then 15 min at RM temp. Cells were then pre-
treated with AMD3100 (1μg/mL) and then treated in specified lanes with the following: 
Ctrl (RPMI 1640), SDF-1α (100ng/mL), AM1241 (1μM), or SDF-1α+AM1241. Cells 
were then placed in 37°C incubator for 30 seconds. Calcium flux assay was analyzed 
immediately after incubation by monitoring the fluorescence at EX=490 nm/Em=525. 
DUOlink Proximity Ligation Analysis Assay 
 (PC-3 and MDA-MB-231) 3x105 cells were treated with the respective ligands 
[Untreated (RPMI), SDF-1 (100ng/mL), AM1241(1 M) SDF-1 + AM1241)] for 1 min 
on coverslips and then were fixed on microscope coverslips using 2% paraformaldehyde 
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(MDA-MB-231) or 100% methanol (PC-3).The receptor-receptor molecular interaction 
in these samples was detected using the DUOlink in situ PLA detection kit (Olink 
Bioscience).Cells were blocked using the kit-provided blocking solution for an hour in a 
pre-heated humidity chamber. Cells were incubated with the primary antibodies in a 
dilution of antibody diluent provided with the DUOlink proximity ligation assay kit 
(1:100) mouse anti-CXCR4 monoclonal antibodies (Santa Cruz Biotechnology) and 
rabbit anti-CB2 monoclonal antibodies(Cayman Chemical) overnight at 37C. PLUS 
anti-rabbit and MINUS anti-mouse PLA probes provided with the kit were then added to 
the cells fixed on the coverslips for 1 hour in pre-heated humidity chamber at 37C. 
Ligation buffer was added to the cells and were incubated in a pre-heated humidity 
chamber for 30 mins at 37C. Amplification buffer (light sensitive) was added to slides 
and incubated in pre-heated humidity chamber for 100 min at 37C. Slides were washed 
and mounted using mounting medium with DAPI and images were reviewed and 
captured using a Zeiss LSM 700 Confocal Microscope. 
Immunofluorescence Assay 
 3x105 cells (PC3 cells) were treated with the respective ligands [Untreated 
(RPMI), SDF-1 (100ng/mL), AM1241(1 M) SDF-1 + AM1241)] for 25 min on 
coverslips and then were fixed on microscope coverslips using 2% paraformaldehyde 
(MDA-MB-231) or 100% methanol (PC-3). Allow cells to fix for 15 minutes at -20°C. 
Fixative was aspirated and the cells were washed three times in PBS for 5 minutes each. 
Each sample was blocked in Blocking Buffer (1% B.S.A/TBS) for 60 minutes. Primary 
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antibody was prepared by diluting in blocking buffer 1:1000. Blocking solution was 
aspirated and primary antibody applied to sample and left to incubate overnight at 4°C. 
After three 5 minute washes samples were incubated with FITC-conjugated secondary 
antibody, samples were diluted in blocking buffer for 1 hour at room temperature in the 
dark. Samples were washed again as described previously and coverslips were mounted 
on slides with DAPI/mounting media and images were reviewed and captured using a 
Zeiss LSM 700 Confocal Microscope. 
Mammalian (siRNA, DNA plasmid) Transfections 
 MDA-MB-231 cells were transfected with 200nM SDF-1α siRNA (Santa Cruz 
Biotechnology, Inc). MDA-MB-231 cells were also transfected with pEGFP-CXCR4 
expression vector. Cells were grown to 80% confluence in 6-well plates and transfected 
the following day by Lipofectamine 2000 (Invitrogen). DNA/siRNA and Lipofectamine 
2000 were premixed in OptiMEM Transfection Reagent for 30 min and then applied to 
the cells. After 24 h transfection, the media was removed and replaced with RPMI and 
the cells were incubated with the indicated treatments for the indicated amount of time. 
After treatment incubation, the media was removed, and cells were washed once with 
cold PBS. Cells were then used in subsequent co-immunoprecipitaion assays, DUOlink 
proximity ligation assays and western blot analyses. 
Live-Cell Imaging Immunofluorescence 
 MDA-MB-231 cells were grown to 70% confluency in 4-well glass chamber 
slides. A working solution of FM4-64 dye was prepared in ddH20 (5μg/mL) and kept on 
ice. 50 L of FM4-64 was added to each chamber for 1 min. and quickly removed. Cells 
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were then treated with the appropriate ligands [Untreated (RPMI), SDF-1 (100ng/mL), 
AM1241(1 M) SDF-1 + AM1241)] on ice. The chamber slide was then taken to LSM 
700 Zeiss Confocal Microscope, placed within the microscope’s incubator and 
endosomal formation was tracked over the course of 30 mins, using time course analysis 
program found within the Zen Black software. 
Flow Cytometry Assays 
 1x106 cells (MDA-MB-231 cells) were treated with the respective ligands 
[Untreated (RPMI), SDF-1 (100ng/mL), AM1241(1 M)  SDF-1 + AM1241)] for 25 min 
MDA MB 231 cells were removed from flasks non-enzymatically using 1x Citric Saline 
and resuspended at 2×105 cells in ice-cold wash buffer (0.2% bovine serum albumin–
phosphate-buffered saline (BSA–PBS)+0·1% sodium azide). Cells were incubated with 
2.5 μg/2×105 cells mouse anti-human CXCR4 (clone 12G5) antibody for 40 min at 4°C.  
Cells were kept on ice to minimize down-modulation of CXCR4 from receptor 
internalization. After washing twice with cold wash buffer cells were incubated with 
fluoroscein isothiocyanate (FITC)-conjugated rabbit anti-mouse immunoglobulin G (IgG) 
in the dark for 30 min at 4°C. Cells were washed twice more and resuspended in wash 
buffer. Fluorescence-activated cell sorting (FACS) analysis was done with an Accuri C6 
flow cytometer (BD Biosciences). Controls received isotype-matched irrelevant mouse 
IgG antibody at the same concentration. 
Statistical Analysis 
 Data are presented as the mean ±SE of at least three independent experiments. 
The data were analyzed for two-way ANOVA or Student t -test. All statistical analyses 
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were done, and all graphs were generated using GraphPad Prism 5.0 software 








Physical Interaction between CXCR4 and CB2 in Prostate and Breast Cancer Cell 
Lines  
To determine whether the CXCR4 and CB2 receptors interact in response to 
ligand stimulation, co-immunoprecipitation analysis was done. PC-3 cells were serum 
starved for 24 hours and then treated with either RPMI 1640 only (control), 100ng/mL of 
SDF-1 in RPMI, 1M of AM1241 in RPMI, or a combination of SDF-1 and AM1241 
at the same concentrations in RPMI for 10 mins.  The cell lysate from each treatment was 
then collected and co-immunoprecipitation analysis was performed on 1 mg of total 
protein, pulling down with protein A/G agarose beads and CXCR4 antibodies and 
immunoblotting with CB2 antibodies. The control lane had very little CXCR4/CB2 
interaction, with the majority of CB2 being found in the supernatant. In the SDF-1 
treated lane, a negligible amount of CB2 appeared to be immunoprecipitated from the cell 
lysate, leaving the majority of CB2 protein in the cell lysate supernatant. AM1241 and 
SDF-1+AM1241 treated lanes had an efficient immunoprecipitation of CB2 protein 
with very little being left in the supernatant (see Figure 4-1). Input lanes of the cell lysate 






                  
 
To confirm the interactions that were observed in our co-immunoprecipitation 
experiments were indeed credible, proximity ligation assays were done. PC-3 as well as 
MDA-MB-231 cells were treated with the same treatments and conditions as described 
above and were the fixed using 2% paraformaldehyde, blocked and incubated with 
primary antibodies for both CXCR4 and CB2 overnight. PLA probes bound to secondary 
antibodies were then added to the cells and incubated in 37C humidity chamber for an 
hour. Ligation and amplification steps were followed as described in the Methodology 
section and images were processed using the Zeiss LSM 700 Confocal microscope. In 
figure 4-A, MDA-MB-231 cells were incubated with rabbit anti-CXCR4 and mouse anti-
CXCR4 antibodies as a positive control for CXCR4/CXCR4 homodimers. This would 
help determine how a positive signal (punctate red dots) would be perceived under the 
microscope. In Figures 4-2(B- F), MDA-MB-231 cells were incubated with rabbit anti-
Figure 4-1. Co-Immunoprecipitation of CB2 with CXCR4. Eluent represents CB2 
protein bound to the beads via CXCR4; Supernatant represents CB2 protein that was 






CB2 antibodies and mouse anti-CXCR4 antibodies for CXCR4/CB2 heterodimers and 
treated as labeled.  
      
 
Positive signals can be seen in the AM1241 treated cell as well as the SDF-1 
+AM1241 treated cells, signifying CXCR4/CB2 protein interaction. In order to fully 
determine whether AM1241 treatment alone was capable of inducing interaction between 
these two receptors or if it was the simultaneous activation of both receptors, activation 
of CXCR4 by endogenous SDF-1 had to be inhibited. Inhibiting CXCR4 activation by 
endogenous SDF-1 was accomplished two different ways: (MDA-MB-231 and PC-3) 
cells were pre-treated with AMD3100, a CXCR4 antagonist for an hour to block receptor 
activation (see Figure 4-3) and cells were also treated with SDF-1 siRNA to knockdown 
endogenous SDF-1. 
Figure 4-2. CXCR4/CB2 interaction in MDA-MB-231 via Proximity Ligation Analysis. 






                              
 
Proximity Ligation Analysis was then performed on these cells to determine 
whether endogenous SDF-1a plays a role in receptor association. Both the AMD3100 
pre-treatments in Figure 4-3. (E, J) and the SDF-1 siRNA transfections in Figure 4-4. 
(B, D) were effective at reducing the positive signaling in the AM1241 treated samples in 
Figure 4-4. (A, C) suggesting that both AM1241 and SDF-1 are required to initiate the 
formation of the heterodimer.  
 
Figure 4-3. CXCR4/CB2 Interaction in AMD3100 pre-treated PC-3 and MDA-MB-






      
 
Effects of CXCR4 and CB2 Heterodimer in Prostate and Breast Cancer Cell Lines 
Once the parameters of the formation of the CXCR4/CB2 heterodimer was found, 
the next stage in this study was to determine what the effects of this heterodimer has on 
downstream signaling and cellular function. In order to assess whether CXCR4 is 
activated while the heterodimer is formed, calcium mobilization assays were done. When 
GPCRs are activated, dissociation of the  subunit initiates the mobilization of calcium 













Figure 4-4. CXCR4/CB2 Interaction in SDF-1 siRNA transfected PC-3 and MDA-





FluoForte Calcium Assay and experimentation was accomplished as described in the 
Methodology section.  
MDA-MB-231 cells were treated with either RPMI 1640 only (control), 
100ng/mL of SDF-1 in RPMI, 1M of AM1241 in RPMI, 1g/mL of AMD3100 in 
RPMI, or a combination of SDF-1 and AM1241 at the same concentrations in RPMI for 
30 secs. Cells were then taken to microplate reader and the calcium flux was monitored. 
SDF-1 treated cells significantly activated calcium in comparison to non-treated 
(control) cells. However, neither AM1241 nor AM1241 +SDF-1 treated cells mobilized 
calcium to a significant level when compared to non-treated (control) cells as well as 
AMD3100 treated cells. 
 In Figure 4-5, AM1241 +SDF-1 treated cells no longer mobilized calcium, 
signifying that CXCR4 isn’t being activated to the same level as SDF-1 alone. In 
addition to determining whether CXCR4 is activated via calcium mobilization, 
determination of activated CXCR4 via phosphorylation of the downstream signaling 
protein, AKT.  
PC-3 cells were treated with either RPMI 1640 only (control), 100ng/mL of SDF-
1 in RPMI, 1M of AM1241 in RPMI, or a combination of SDF-1 and AM1241 at the 
same concentrations for 10 mins (see Figure 4-6). Cell lysates were then probed for total 
AKT and phospho-AKT. SDF-1+ AM1241 treated cells had decrease in phosphorylated 





                    
 
This decrease in phosphorylated AKT signifies that CXCR4 wasn’t being 
effectively activated leading to an inhibition of the AKT signaling cascade in cells 
simultaneously treated with the ligands AM1241 and SDF-1 (see Figure 4-6).  
Finally, to determine whether abrogation of CXCR4 signaling has had a 
functional effect on the cell, the migration of the MDA-MB-231 breast cancer cells was 
analyzed. MDA-MB-231 cells were plated in the upper chamber of 8.0m transwell 
inserts and the appropriate volume of treatment solutions at pre- determined 
concentrations were placed in the lower chamber; it was at this time that cells were 
allowed to migrate to the lower chambers of the transwell migration plates for five hours 
at 37C in 5% CO2.  






                      
 
Inserts were then removed from treatment media and non-migrated cells were 
removed from insert. Cells were then fixed and stained with methanol and Hemacolor 
stain. Five representative fields of each insert were counted on a light microscope and the 
migration index was then calculated and graphed. In Figure 4-7, cells treated with SDF-
1+AM1241 had a significantly diminished migratory potential when compared to cells 
treated with SDF-1 only. In Figure 4-7.B, cells were treated with an alternative 
chemokine, CXCL1, an agonist for the CXCR2 receptor, to determine whether or not this 
heterodimer formation was exclusive to CXCR4 and CB2 or whether any chemokine 
receptor would work and a similar phenomenon was observed. There was a decrease in 
the number of migrated cells treated with CXCL1/AM1241 when compared to cells 
treated with CXCL1 alone, indicating that the decrease in migration is an effect of any 
GPCR that can form heterodimers and not just of the heterodimer of CXCR4/CB2.  In 
Figure 4-7 (C), cells were pre-treated with AM630, a CB2 antagonist, to determine 
whether migration can be recovered be blocking activation of the CB2 receptor. Cells 
were then treated with SDF-1, AM1241, and the combination of the two. When the 
SDF-1/AM1241 cells were pre-treated with AM630, the inhibition of migration that 






was observed earlier was no longer seen. Pre-treating with a CB2 antagonist, AM630, 
restored the migratory potential of these cells, by blocking the binding of the CB2 
agonist, AM1241. In Figure 4-7(D), an alternate agonist for CB2, JWH-015, was used to 
determine whether the inhibitory effects that were observed with AM1241/SDF-1 
treated cells were specific to the AM1241 agonist or whether another agonist can be used 
to illicit this effect. When cells were treated with JWH-015 instead of AM1241, similar 
results were achieved where cells weren’t strongly induced to migrate, indicating that this 












CXCR4/CB2 Heterodimer Inhibits CXCR4 Internalization 
CXCR4/CB2 heterodimers may have another unintended effect on the 
internalization of the CXCR4 receptor protein. In addition to halting downstream 
signaling, the formation of the heterodimer may be inhibiting the internalization of 
CXCR4, which may result in downregulating signaling. In order to substantiate this 
initial observation, flow cytometry analyses were performed on cells treated with our 
array of agonists (see Figure 4-8).  










Cells were treated with either RPMI 1640 only (control), 100ng/mL of SDF-1 in 
RPMI, 1M of AM1241 in RPMI, 1g/mL of AMD3100 in RPMI, or a combination of 
SDF-1 and AM1241 at the same concentrations in RPMI for 25 mins. Each sample of 
cells were then enzymatically removed and incubated with CXCR4 primary antibodies 
for 40 mins at 4C. Cells were then washed and incubated with FITC-conjugated 
secondary antibodies for 30 min at 4C. After the final washes cells were analyzed for 
cell surface CXCR4 using Accuri C6 Flow cytometer. In Figure 4-8 A, the cell surface 
expression of CXCR4 in the SDF-1 treated cells after 25 mins was significantly 
decreased in comparison to the untreated (control) cells indicating internalization. When 
the CXCR4 surface expression of SDF-1 treated cells is compared to that of the SDF-
1+AM1241 treated cells, CXCR4’s expression is significantly higher on the surface of 
the combination treated cells, implying that there is an inhibition of internalization due to 
simultaneous treatment. Treatment with the AMD3100, CXCR4 antagonist also seemed 
to halt internalization of CXCR4 after 25 mins. In Figure 4-8 B, pre-treating with the 
CB2 antagonist restored the internalization of CXCR4 in simultaneously stimulated cells. 
To qualitatively assess whether CXCR4 internalization is being inhibited in 
response to simultaneous stimulation, immunocytochemistry analysis was performed on 
MDA-MB-231 cells transfected with pEGFP-CXCR4 expression vector (see Figure 4-9). 
Cells were then treated with either RPMI 1640 only (control), 100ng/mL of SDF-1 in 
RPMI, 1M of AM1241 in RPMI, or a combination of SDF-1 and AM1241 at the same 
concentrations in RPMI for 25 mins. After treatment cells were fixed mounted and 







In Figure 4-9, CXCR4 can be seen on the cell membrane of non-treated cells, 
however in SDF-1 treated cells, CXCR4 can be seen co-localizing and gathering into 
potential endosomes for internalization. In the AM1241 treated cells, CXCR4 is still very 
much present on the cell membrane when compared to the SDF-1 treated cells. In the 
cells treated simultaneously with SDF-1 and AM1241, CXCR4 can be seen being 






internalized, however the internalization seen is appreciably less than that observed in the 
SDF-1 treated cells (see Figure 4-9). 
Lastly, in order to biochemically assess whether CXCR4 internalization is being 
halted, this study explored whether essential internalization machinery was being 
recruited to CXCR4 (see Figure 4-10). The recruitment of -arrestin and Rab5 GTPases 
to CXCR4 was assessed via co-immunoprecipitation assays. MDA-MB-231 cells were 
treated with either RPMI 1640 only (control), 100ng/mL of SDF-1 in RPMI, 1M of 
AM1241 in RPMI, or a combination of SDF-1 and AM1241 at the same concentrations 
in RPMI for 25 mins at 37C. The cell lysate from each treatment was then collected and 
co-immunoprecipitation analysis was performed on 1 mg of total protein, pulling down 
with protein A/G agarose beads and CXCR4 antibodies and immunoblotting with either 
-arrestin and Rab5 antibodies. In Figure 4-10.A, -arrestin is being recruited to CXCR4 
when SDF-1 and AM1241 are individually present, however when cells were treated 
with SDF-1 and AM1241 simultaneously, less -arrestin is associated with CXCR4. In 
Figure 4-10.B, Rab5 is being recruited to CXCR4 when SDF-1 and AM1241 are 
individually present, however when cells were treated with SDF-1 and AM1241 
simultaneously, less Rab5 is associated with CXCR4. These results indicate that the 
potential of CXCR4 to be internalized is being inhibited in response to an agonist-
induced heterodimer. 
To observe inhibition of internalization in real-time, time course assays were done 






                     
 
MDA-MB-231 cells were plated in glass bottom chamber slides and serum 
starved for 24 hours. Cells were then incubated for 1 min with the FM4-64 dye and then 
treated with either RPMI 1640 only (control), 100ng/mL of SDF-1 in RPMI, 1M of 
AM1241 in RPMI, or a combination of SDF-1 and AM1241 at the same concentrations 
in RPMI on ice. Cells were immediately taken to the confocal microscope and placed into 
the 37C/5% CO2 incubator associated with the microscope. A time course experiment 
was run for 30 mins to measure endosomal formation and internalization. SDF-1 treated 
cells were observed forming endosomes, signified by the “red dots” appearing within the 
cells’ cytoplasm. In the non-treated (Ctrl), AM1241, and the combination treated cells, 
very little endosomes can be seen forming over the time of the experiment, though there 
were some already formed endosomes initially, no new endosomes were seen 





























                
 
 
Figure 4-11. Inhibition of Endosomal Formation in Simultaneously Stimulated Cell 








 CXCR4/CB2 heterodimers are another addition to a growing list of heterodimers 
that play a role in altering the normal function of the component GPCRs within their 
respective complex. CXCR4’s role in the progression of cancer from benign to malignant 
makes it a key target for metastasis related therapy. The functional CXCR4 expression 
within cancer and its effects on the cancer cell are easy enough to address, however it is 
CXCR4’s widespread role in the cells of the immune system that make it a problem to 
treat with conventional CXCR4 antagonists. Being able to take advantage of the 
association between CXCR4 and CB2 when they are simultaneously stimulated provides 
an alternative strategy to traditional CXCR4 targeted treatments. Of course, this line of 
treatment has to go through the various degrees of pharmacological testing required 
before it can be taken seriously as a viable treatment option for combating metastatic 
cancer. However, the results from our study provide the first steps of a potential 
cannabinoid therapy for cancer. 
In order to completely delineate the parameters in which CXCR4 and CB2 
interact, pinpointing an interaction domain is paramount. In this study, a single nucleotide 
mutation was made to CXCR4 that, in and of itself, did not alter the function of CXCR4 
but would, in theory, disrupt CXCR4’s ability to form a heterodimer (see Appendix A-2) 
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However, studies have shown that single nucleotide mutations are not enough to 
alter heterodimer formation but instead whole areas of the transmembrane need to either 
be removed or replaced. The problem with altering CXCR4’s sequence so drastically lies 
within trying to determine whether any functional change seen in the protein is attributed 
to the heterodimer or the mutation. Designing and treating cells with peptides that interact 
with various areas on the CXCR4 protein may provide a way to determine the interaction 
domain of CXCR4 without having to mutate the receptor. This technique was 
accomplished successfully by Wang et. al. (56) by using a peptide mimicking CXCR4 
transmembrane 4 (TM4) to disrupt homodimer formation.  
The cannabinoid receptor 2 (CB2) is most closely associated with the immune 
system and repression of immunological response through regulation of the transcription 
factor, CREB (cAMP response-element binding protein). However, in our studies we 
proposed an addition to the activation of CREB for the regulation of immunological 
response, that being CB2/CXCR4 heterodimerization. Due to the fact that both the CB2 
and the CXCR4 receptors are found within the immune system, a legitimate inquiry 
would be what are the effects that establishing a line of treatment based on this study 
would have on the immune system, if any. The most obvious conclusion would be that it 
would suppress the immune system by inhibiting the chemotaxis of immune cells to sites 
of high SDF-1 concentration and maybe even reducing the production of inflammatory 
chemokines. The possibility of unsolicited immunosuppression as a side effect may lead 
one to inquire how this therapeutic strategy is better than the classical CXCR4 
antagonist-related therapy. A clinical study was done to determine the effectiveness and 
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toxicity of the CXCR4 antagonist, LY2510924 in 45 patients with varying types of 
advanced cancer. What was found was that after the final phase of the treatment, there 
were increases in CD34+ cells and neutrophils in peripheral blood with no increase in 
circulating tumor cells. This signified a mobilization of CD34+ hematopoietic stem cell 
homing from the bone marrow and an activation of neutrophils which can lead to 
neutrophilia. Two of the 45 patients in the study experienced dose-limiting toxicities of 
Grade 3 increased neutrophil count, which disqualified them from the study (57.) In this 
study, the inhibitor directly targeted the receptor, however in our study the activity of our 
treatment is directly proportional to the expression of not only CXCR4, but both CXCR4 
and CB2. The increased aberrant expression of the CB2 receptor in cancer cells compared 
to CD34+ HSCs (58, 59) and neutrophils (59) makes the effect of our hypothetical 
treatment more effective in cancer and decreases the possible side effects associated with 
CXCR4 antagonism.  
Further study of this phenomenon to is required to better understand how GPCRs 
can form and maintain heterodimers. Determining whether the CB2/CXCR4 heterodimer 
is a one-to-one interaction or oligomeric in nature is an area of study that still needs to be 
explored. Also, determining how many interacting CB2 proteins need to be expressed 
within a cell for abrogation of CXCR4 function is an important question especially when 
it comes to pharmacodynamic studies. Gaining a full understanding of our heterodimer 
will contribute to a potential treatment for metastatic cancer by providing clinicians with 









 To conclude, the simultaneous stimulation of the GPCRs, CXCR4 and CB2, with 
their respective ligands lead to an abrogation of SDF-1 -mediated signaling. In this 
study we used PC3 cells as a prostate cancer cell model and MDA-MB-231 cells as a 
breast cancer cell model due to their endogenous expression of both these receptors and 
because they are both standard cell lines for these diseases. When these cells were treated 
with biologically relevant concentrations of their ligands, we determined through 
proximity ligation analysis and co-immunoprecipitation assays that these receptors were 
associated with each other, forming potential heterodimers. To fully determine whether 
CXCR4 signaling was abrogated, phosphorylation of downstream signaling molecules 
ERK and AKT was assessed. When CXCR4 is activated, ERK and AKT are 
phosphorylated however when these cells were simultaneously treated with their 
respective ligands, these signal molecules were phosphorylated to a lower degree.     
Calcium mobilization is increased when GPCRs are activated and in order to determine 
whether CXCR4 was activated during simultaneous stimulation calcium mobilization 
assays were done. Calcium was found to be mobilized to a lesser degree in 
simultaneously stimulated cells when compared to SDF-1 treated cells signifying a halt  
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in the activation of CXCR4. In order to assess what functional effects the heterodimer has 
on the cell, migration assays were performed. The simultaneously stimulated cells didn’t 
migrate as effectively as the cells treated with SDF-1 only however when cells were 
pre-treated with the CB2 antagonist, AM630, the migratory ability of these cells returned. 
In theory, the AM630 antagonist, would block the CB2 agonists, hypothetically 
disrupting the heterodimer. Once the heterodimer is disrupted, the migratory ability is 
returned to the cells.  
One observation that was made in regards to CXCR4/CB2 heterodimerization was 
that CXCR4 didn’t seem to be internalizing effectively when cells were treated 
simultaneously with SDF-1 and AM1241 when flow cytometry analysis was performed. 
Flow cytometry analysis experiments determined that CXCR4 remained on the surface of 
MDA-MB-231 cells when simultaneously stimulated. Also, when cells were pre-treated 
with AM630, CXCR4 internalization was recovered in simultaneously stimulated cells. 
The inhibition of CXCR4 internalization was also confirmed by immunocytochemistry 
and by co-immunoprecipitation of CXCR4 with internalization machinery (-arrestin and 
Rab5). Lastly, time course assays were done to measure in real-time the internalization of 
CXCR4 in individually treated cells vs simultaneously treated cells.  
Understanding the mechanisms surrounding this heterodimer will have a great 
impact on the field GPCR heterodimerization in the future by adding to the base of 
existing information. The list of GPCRs that have been found to interact is growing and 
with our work on CXCR4 and CB2, we have contributed to that databank, hopefully 
advancing relevance of this field. In our study, we see how GPCRs can effectively 
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regulate each other through co-stimulation and heterodimerization, creating a synergistic 
effect that can alter a GPCRs normal function, in our case, CXCR4’s ability to mobilize 
cells toward its ligand. Other GPCRs may have this ability and by uncovering the 
parameters of their heterodimerization, researchers may be able to manipulate a host of 
alternative GPCR functions via co-stimulation. Building on the knowledge uncovered in 
this study will no doubt provide answers to effectively harness the therapeutic potential 
of GPCRs that remain not yet accessed by today’s science. 




OVERVIEW OF PROXIMITY LIGATION ASSAY/ IP OF MUTANT CXCR4  
           
                                   













Appendix 1. Overview of Proximity Ligation Assay. 
Appendix 2. Co-Immunoprecipitation of CB2 with HA-Tagged CXCR4 
Mutant (Y135F)- A plasmid containing HA-Tagged CXCR4 Y135F mutants 
were transfected into MDA-MB-231 cells. Immunoprecipitation of expressed 
CXCR4 mutant from cell lysates using HA antibodies. Immunoblot analysis 
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